Literature DB >> 19945237

Factors related to increased daytime sleepiness during the menopausal transition as evaluated by the Epworth sleepiness scale.

Peter Chedraui1, Faustino R Pérez-López, Marcela Mendoza, María L Leimberg, María A Martínez, Varinia Vallarino, Luis Hidalgo.   

Abstract

BACKGROUND: Sleep disorders and sleep-apnea/hypopnea syndromes are very frequent in women, being misdiagnosed in many cases. The menopause, regardless of age, is associated to poor sleep quality and daytime sleepiness that can lead to impaired quality of life, and reduced productivity and functioning.
OBJECTIVE: To assess daytime sleepiness and related risk factors among middle aged Ecuadorian women using the Epworth Sleepiness Scale (ESS).
METHODS: In this cross-sectional study 149 women aged 40-59 years were assessed for hot flush presence and intensity using the Menopause Rating Scale (MRS) and requested to fill out the ESS and a questionnaire containing personal and partner data.
RESULTS: Mean age of surveyed women was 47.6+/-5.5 years, with 67.8% having less than 12 years of schooling, 33.6% being postmenopausal, and 2.7% on hormone therapy. A 10.1% were current smokers and 20.8% were sedentary. According to the MRS (item 1) 51.7% presented hot flushes, which were graded as severe-very severe in 42.8% of cases. Regarding the partner (n=132), erectile dysfunction was present in 10.6%, premature ejaculation 6.1% and 17.4% abused alcohol. Mean total ESS score was 8+/-4.4 (median 8), with 33.6% considered having some degree of daytime sleepiness (ESS score >or=10). Logistic regression analysis determined that postmenopausal status (OR 6.58, CI 95% [2.51-17.23], p=0.001), sedentarism (OR 3.43, CI 95% [1.14-10.26], p=0.02) and hot flush presence (OR 2.61, CI 95% [1.02-6.65], p=0.04) among women were risk factors for increased daytime sleepiness (ESS total score >or=10) whereas partner faithfulness decreased this risk (OR 0.47, CI 95% [0.24-0.90], p=0.02).
CONCLUSION: Increased daytime sleepiness in this middle aged series was related to female (hormonal status and sedentarism) and partner factors; several which are susceptible of intervention.

Entities:  

Mesh:

Year:  2009        PMID: 19945237     DOI: 10.1016/j.maturitas.2009.11.003

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

1.  Consistently high sports/exercise activity is associated with better sleep quality, continuity and depth in midlife women: the SWAN sleep study.

Authors:  Christopher E Kline; Leah A Irish; Robert T Krafty; Barbara Sternfeld; Howard M Kravitz; Daniel J Buysse; Joyce T Bromberger; Sheila A Dugan; Martica H Hall
Journal:  Sleep       Date:  2013-09-01       Impact factor: 5.849

2.  Influence of menopause on adipose tissue clock gene genotype and its relationship with metabolic syndrome in morbidly obese women.

Authors:  Juan José Hernandez-Morante; Cecilia Gomez-Santos; Javier Margareto; Xavier Formiguera; Carlos Manuel Martínez; Raquel González; Olga Martínez-Augustín; Juan Antonio Madrid; Jose María Ordovas; Marta Garaulet
Journal:  Age (Dordr)       Date:  2011-09-07

3.  COMParative Early Treatment Effectiveness between physical therapy and usual care for low back pain (COMPETE): study protocol for a randomized controlled trial.

Authors:  Daniel Rhon; Julie Fritz
Journal:  Trials       Date:  2015-09-23       Impact factor: 2.279

Review 4.  Instruments to study sleep disorders in climacteric women.

Authors:  Álvaro Monterrosa-Castro; Katherin Portela-Buelvas; Marlon Salguedo-Madrid; Joulen Mo-Carrascal; Carolina Duran-Méndez Leidy
Journal:  Sleep Sci       Date:  2016-11-18

5.  Influence of sleep disturbances on quality of life of Iranian menopausal women.

Authors:  Zohreh Yazdi; Khosro Sadeghniiat-Haghighi; Amir Ziaee; Khadijeh Elmizadeh; Masomeh Ziaeeha
Journal:  Psychiatry J       Date:  2013-11-05

Review 6.  Role of Ovarian Hormones in the Modulation of Sleep in Females Across the Adult Lifespan.

Authors:  Alana M C Brown; Nicole J Gervais
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.